Aiming to support drug developers in issues related to market insights, engagement, and access, Synaptiq enters the market backed by three consultancy agencies.
LGC announces the addition of Quanterix’s HD-X platform to its offering, enabling automated development and performing of immunoassays for ‘unprecedented insights’ into disease biology as well as drug efficacy and safety.
The outsourced service providers have signed a new collaboration agreement to provide global pharmaceutical and biotechnology clients access to electrophysiology and ion channel screening.
Quintiles will provide its open source code to tech giant Apple’s ResearchKit framework to help create more efficient and integrated clinical trial apps.
Outsourcing-pharma.com readers want the acronym CRO to stand for 'contract research organisation' according to the results of a snap poll we ran yesterday.
Outsourcing-pharma.com witnessed a fascinating debate on the definition of ‘CRO’ yesterday with terms like 'collaboration' and 'release' being suggested as potential alternatives.
PPD posted an improved set of financials for Q2 days after announcing a review of its long-term plan and capital structure following speculation it was looking for a buyer.
Lab Research's main Canadian lender has obtained an order appointing receivers under section 243 of the bankruptcy and insolvency act after the firm's US private equity suitor lost interest in a takeover.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at INC Research, Emerald BioStructures and ClinOps.
PPD signs clinical imaging and formulation development collaborations, reorganises reporting units and cites “improved performance in emerging markets” and spending controls as key to third quarter gains.
Outsourcing-pharma takes a look at all the latest developments in the rapidly expanding drug development imaging sector with news from Aspect and Medisco, VirtualScopics and ABX-CRO and ACR Image Metrix.
CRO NexMed has received a $2.7m (€2.0m) cash boost, which improves its financial situation and provides funds to develop its NexACT technology for oral and transdermal delivery.
Novotech says its new “management hub” in Kuala Lumpur, Malaysia will serve as a base for expansion in the booming Asia-Pacific contract research sector.
Encorium has abandoned plans to sell its Finnish unit, Encorium OY, citing its new strategic focus and recent contract wins as the basis for the decision.
Axiom Accelerated Patient Recruitment hopes its new range of SMS, text messaging, services can help CROs and pharma sponsors reach more potential study participants.
CRO Averion is planning to become a private company to reduce expenditure on auditor fees, which could realise savings of $805,000 (€561,000), and allow management to better focus on long-term goals.
19 out of 21 pharmaceutical companies surveyed by Cutting Edge Information ranked a contract research organisation’s ability to hit trial deadlines as either “extremely important” or very “important,” making it the top quality identified by respondents.
Kendle International has posted impressive third quarter results, despite seeing a dramatic increase in the number of contract cancellations during the period.
US-based contract research organisation Medelis has founded a European division, Medelis Europe, to bring its expertise in oncology clinical trials design and management to customers wanting to launch drugs in Europe.
Management of publicly-traded Synexus have agreed to the £18.1m
(€25.7m) sale of the company to a private equity firm that has
promised to fund its global expansion ventures.
PharmaNet has reported second quarter results that place it back in
the red after it had only just clawed its way back into the black
in the first quarter, following a string of quarterly losses.
PPD has posted positive financial results for the second quarter of
the year in net contrast to its lacklustre performance in Q1, but
cut its earning outlook for the full year.
Biophage has completed the final phase of its CRO business
restructuring in preparation to meet the expected demand in
immunotoxicity testing, in which its requirement stems from
increasing legislation that calls for stricter standards.
